Inotek Pharmaceuticals Corp., of Lexington, Mass., plans to apply $21 million in proceeds from a venture financing and $7 million in venture debt financing to advance its A1 subtype adenosine mimetic for glaucoma and ocular hypertension. The funds will allow it to begin a Phase II study of trabodenoson in combination with latanoprost in late 2013.